US FDA approves AstraZeneca's diabetes drug for treating heart failure risk

US FDA approves AstraZeneca's diabetes drug for treating heart failure risk

AstraZeneca Plc said on Monday U.S. regulators approved its diabetes drug Farxiga to be used as a treatment to reduce the chances of hospitalization for heart failure in adults with type-2 diabetes and other cardiovascular risks.

FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the
FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid/File Photo

REUTERS: AstraZeneca Plc said on Monday U.S. regulators approved its diabetes drug Farxiga to be used as a treatment to reduce the chances of hospitalization for heart failure in adults with type-2 diabetes and other cardiovascular risks.

The approval by the U.S. Food and Drug Administration is based on results from the DECLARE-TIMI 58 clinical trial, the British drugmaker said and follows a similar approval https://www.astrazeneca.com/media-centre/press-releases/2019/forxiga-label-updated-in-the-eu-in-type-2-diabetes.html by the European authorities in August.

Diabetes is associated with a high risk of heart failure.

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun Koyyur)

Source: Reuters

Bookmark